Memorial Sloan Kettering Cancer Center New York, NY
Disclosure(s):
Elena Mead, MD: No relevant financial relationship(s) to disclose.
CAR T cell therapy is an emerging treatment for solid and liquid cancers that is rapidly becoming commonly used in the setting of relapsed and refractory disease. 5 FDA products are currently available and more soon to be approved. Many Critical Care physicians are becoming familiar with the presentation of Cytokine Release Syndrome and Immune effector Cell-Associated Neurotoxicity Syndrome and their management. The other toxicities, Cardiotoxicity, HLH, renal toxicity, hepatotoxicity, DIC though slightly less common, are now recognized as either important aspects of CRS or separate important actionable toxicities of immune effector cell therapy. The goal of this lecture is to review presentation and management of several toxicity profiles.
